Cooper Companies: The Activist Letter That Arrived Right After the Answers Were In

Jana Partners wants Cooper Companies to replace its CEO, appoint a new board chair, and weigh strategic alternatives for its contact lens business. The letter, made public on September 18, is the latest escalation in a year-long activist campaign at the $10.5 billion medical device company.

Except the answers to Jana's main questions had already been delivered — eight days earlier.

On September 9, Cooper reported third-quarter fiscal 2026 results, announced the completion of a strategic review, and decided to keep its CooperSurgical fertility business after evaluating offers from buyers. The same day, the board expanded its share repurchase authorization from $2 billion to $3 billion, signaling confidence in the combined structure. Then Jana's letter landed, asking the board to do almost the opposite.

The timing matters because it reveals what this activist campaign is actually about — and it changes how you read the numbers.

What the business is actually doing

Cooper operates two divisions. CooperVision, the contact lens business, generated $717 million in the third quarter — roughly two-thirds of consolidated revenue of $1.066 billion. CooperSurgical, the fertility and medical device unit, produced $349 million. The full-year 2025 revenue was $4.09 billion, up 5% from the prior year.

The margins are what catch the eye. Gross margin sits at roughly 66%. Non-GAAP operating margin in the third quarter was 26.3%, up from 26% a year earlier. That's the kind of profitability you don't get from a commodity business. Contact lenses, especially premium daily silicone hydrogels like Cooper's MyDay line, carry real pricing power.

The cash flow is stronger still. Third-quarter free cash flow was $273 million — a record for a single quarter. Year-to-date free cash flow reached $528 million, up 86% from the same period last year. On a trailing twelve-month basis, Cooper generated $678 million in free cash flow, up nearly 65% year over year. Capex sits at $355 million annually, modest for a company of this scale.

The balance sheet shows $4.3 billion in total debt against $8.3 billion in equity, a debt-to-equity ratio of roughly 0.3. There's $155 million in cash on the books. Interest expense in the quarter was $21.5 million — trivial relative to cash generation. This is not a company that needs to sell assets to survive a downturn.

Then why is the stock down 32% year-to-date?

The decline isn't about collapsed margins or a broken business model. It's about three specific events that clustered in the past few months.

First, the strategic review of CooperSurgical created uncertainty about the company's structure for months. Then, when the review concluded, Cooper lowered its full-year fiscal 2026 revenue forecast from $4.29–$4.32 billion to $4.23–$4.25 billion and cut adjusted earnings guidance from $4.58–$4.66 to $4.51–$4.55 per share. And the reason for the cut wasn't weakness in underlying demand — it was a deliberate decision to accelerate inventory reduction at CooperVision.

Here's the mechanism. U.S. distributors had built up excess inventory — purchases ahead of price increases, customer consolidation, IT system upgrades, and stock from newly won private-label contracts. Cooper could have let that inventory dissipate gradually over several quarters, smoothing the revenue impact. Instead, management accelerated the correction, front-loading the revenue drag into Q3 and Q4 of fiscal 2026. Without the inventory reductions, Americas revenue for the quarter would have grown approximately 5%.

The trade-off is real. You take the hit now or you carry the distortion forward. Cooper chose to clear the channel rather than let inflated distributor stock create a demand cliff later. That's a management decision you can disagree with on timing, but it's not operational failure.

The activist's actual case

Jana holds approximately 3.58 million shares — a 1.8% stake. That's enough to be heard at a shareholders' meeting but not enough to control an outcome. The letter cites chronic underperformance, inventory mismanagement, and poor capital allocation. It asks for a new CEO, a new board chair, and engagement with buyers for CooperVision.

There's a second activist in the background too. Browning West, which invested more than $500 million and holds roughly 4% of the company, has been pushing since last November. Browning West has seen some movement: former Steris CEO Walter Rosebrough was appointed to the board, and Cooper has said it added two new independent directors with healthcare and medical device experience. That's the kind of concrete governance change that shows activists can move the needle at Cooper.

But Jana's demands go further — and arrive at a moment when the board has just answered the questions Jana claims need answering. The strategic review is done. The board evaluated offers for CooperSurgical and decided to retain it, citing a "valuation disconnect" caused by a new competitive entrant in the non-hormonal IUD market and the company's fertility litigation settlement. The board concluded that continued ownership serves shareholders better than a transaction at current valuations.

Then Jana asks them to start over.

The valuation question

This is where the investor's actual problem lives. Not whether Jana is right or wrong on governance, but whether the stock price reflects something the market has gotten wrong about the business.

At roughly $55 a share and a $10.5 billion market cap, Cooper trades at 18.4 times trailing earnings and 13.9 times EBITDA. The book value multiple is 1.26. Free cash flow yield on a trailing basis is approximately 6.4%. Forward P/E is 27, which reflects the market pricing in the near-term inventory drag.

Compare that to Bausch + Lomb, the contact lens rival Jana previously suggested as a combination partner. Bausch + Lomb has a $6 billion market cap but trades at negative earnings multiples due to restructuring charges, with an EV/EBITDA of 15.4 — higher than Cooper's 13.9 despite a weaker earnings profile.

The 1.26x book value multiple is the number that deserves attention. A company generating 66% gross margins and $678 million in free cash flow annually, trading at slightly above book value with a clean balance sheet — that's either a market that's over-discounting temporary headwinds, or it's a signal that something structural is eroding the asset base.

The evidence points to the former. The inventory correction is a timing issue, not a demand issue. MyDay posted double-digit growth in Europe and double-digit consumption growth in the Americas. MiSight, the myopia-management lens, grew organically 20%. CooperVision is expanding its U.S. sales force to reach 5,000 additional eye-care offices. The pipeline is there.

The tax environment adds a layer of durability too. Cooper recorded a $307 million discrete tax benefit from the resolution of a U.K. tax examination, and management indicated the favorable tax structure should persist for at least another 10 years. The effective tax rate is expected to rise modestly from 15.5% to 17.5% next year, but that's still well below the statutory rate and supports cash flow.

What to make of the proxy threat

Jana has until early January to nominate directors. That's the calendar that drives this campaign as much as the business case. A proxy fight is expensive, messy, and uncertain — but it also creates a price catalyst if the market thinks the board might change.

The real test for Jana isn't the letter. It's whether enough institutional holders agree that CooperVision is worth more as a standalone business or combined with Bausch + Lomb. That's a structural argument, and it cuts both ways. A pure-play contact lens company could trade at a premium multiple. But separation also means losing the diversification that CooperSurgical provides, the combined overhead savings, and the $678 million in annual free cash flow that the current structure generates.

There's also an incentive question worth sitting with. Jana's 1.8% stake means the activist gains proportionally from any uplift — including one driven by restructuring pressure rather than operational improvement. That's standard activist economics. It doesn't make the case wrong, but it does mean the demands are calibrated to create market reaction, not necessarily to reflect the optimal long-term structure.

The gap

Cooper Companies isn't a distressed asset trading below liquidation value. It's a cash-generative business with 66% gross margins that took a planned revenue hit to clean up distributor inventory, then got hit by an activist letter that asked the board to undo decisions it had just made.

The stock at 18x trailing earnings and 1.26x book, generating $678 million in annual free cash flow with manageable leverage — that gap between price and the underlying cash-generating asset is the investor's opening. But it's not a gap created by structural decline. It's a gap created by temporary drag, activist noise, and a market that prices the next quarter's inventory impact more heavily than the next three years' cash flow.

The question isn't whether Jana's demands are reasonable. It's whether the market has confused a deliberate inventory correction with a failing business, and whether the activist timeline is creating a wider discount than the fundamentals warrant. The financial test is simple: can CooperVision resume growth once the channel clears, and does the combined company generate enough cash to justify its current valuation? On those two points, the evidence doesn't yet say no.